Corrigendum to "The novel peripherally active cannabinoid type 1 and serotonin type 3 receptor agonist AM9405 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome" [Eur. J. Pharmacol. (2018), 836 34-43]
1 Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, Lodz, Poland.
2 Center for Drug Discovery, Department of Pharmaceutical Sciences, Department of Chemistry & Chemical Biology, Northeastern University, Boston, MA, United States.
3 Department of Pharmaceutical Sciences, Northeastern University, Boston, MA, United States.
4 Center of Endoscopy, Starnberg, Germany and Department of Medicine 2, Ludwig-Maximilian University Munich, Munich, Germany.
5 Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, Lodz, Poland. Electronic address: jakub.fichna@umed.lodz.pl.